Phase 1 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older.
• People who have an advanced solid tumour that has been confirmed by laboratory testing of tissue or cell samples.
• People whose tumour type and treatment history match one of the specific study groups (arms) — for example, tumours with certain gene mutations (such as HRAS, KRAS, NRAS, or KRAS G12C), specific cancer types such as lung cancer, bowel cancer, pancreatic cancer, or kidney cancer, or people who have already received certain prior treatments (confirm specific arm eligibility with trial site).
• People whose cancer can be measured using standard imaging criteria (known as RECIST v1.1).
• People who are in reasonably good general health, based on a standard performance score of 70 or higher, with no notable decline in the past two weeks.
• People with adequately functioning liver, kidneys, hormone-producing glands, and blood cell counts.

Who may not be able to join:

• People who have received any anti-cancer treatment within 14 days (or within a shorter timeframe based on the specific drug used) before the trial start date.
• People who have previously been treated with a drug from a class called farnesyltransferase inhibitors (FTIs) or an HRAS inhibitor.
• People who have had major surgery (other than minor local procedures) within 28 days before the trial start date and have not fully recovered.
• People who have cancer that has spread to the spinal cord, the lining of the brain or spinal cord, or who have active brain metastases causing symptoms.
• People who still have significant side effects from previous cancer treatments that have not returned to their normal baseline levels (hair loss is an exception).
• People who have had an active or previously diagnosed autoimmune or inflammatory condition within the past 5 years (some exceptions may apply — confirm with trial site).
• People who currently have an active, uncontrolled infection caused by bacteria, a virus, or a fungus that requires treatment through the bloodstream.
• People who are unable to swallow tablets or capsules, or who have a digestive system condition that could affect how the trial medicines are absorbed.
• People with significant heart or blood vessel problems, including a heart attack, unstable chest pain, or stroke within the past 6 months, certain abnormal heart rhythm measurements, or moderate-to-severe heart failure.
• People who have had another unrelated invasive cancer within the past 2 years.

Important: Always verify eligibility with the trial site directly before applying.